WCN26-4574 DISCONTINUATION OF RENIN-ANGIOTENSIN SYSTEM INHIBITORS AND CLINICAL OUTCOMES: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIAL

Read full text Summarise with VIRAT
Authors: Taihei Suzuki, Hiroki Nishiwaki, Yoshifusa Abe, Yoshitaka Watanabe, Shunsuke Yoshida, Nobuhiro Kanazawa, Hisashi Noma, Erika Ota, Hirokazu Honda, Takeshi Hasegawa
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

The renin-angiotensin system inhibitors (RASi), such as angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers, angiotensin receptor-neprilysin inhibitor, and mineral corticoid receptor antagonist are sometime discontinued because of their adverse events in clinical practice. However, the effects of RASi withdrawal have not been elucidated fully. We performed systematic review and meta-analysis using the RCTs data from large database and registry archives to comprehensively examine the current landscape of the effects of RASi discontinuation.

Fields of Study & Subjects

Renin-Angiotensin System Studies Chronic Kidney Disease and Diabetes Blood Pressure and Hypertension Studies

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104786–104786
Publication date
25 March 2026
Language
EN